APVO ▼ -12.7% - Aptevo Therapeutics Inc. $APVO - Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML Aptevo Therapeutics fell 12.7% despite reporting a 93% clinical benefit rate for its mipletamig triplet combination in difficult-to-treat TP53-mutated frontline acute myeloid leukemia, suggesting investors may have viewed the clinical data as insufficient to offset existing concerns about the company's pipeline or financial position. 03-SEP-2026 08:05 AM ET